Close Menu

NEW YORK - A group of mental health advocacy organizations have sent a letter to the US Department of Health and Human Services and the US Food and Drug Administration, imploring FDA to reconsider its recent actions curtailing the activities of pharmacogenomic test providers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.